iBio (NASDAQ:IBIO - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Sunday, Wall Street Zen reports.
A number of other research firms have also weighed in on IBIO. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of iBio in a research report on Monday, September 21st. HC Wainwright initiated coverage on iBio in a research note on Thursday, September 17th. They set a "buy" rating and a $7.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $6.00.
Check Out Our Latest Report on IBIO
iBio Stock Performance
IBIO stock opened at $0.82 on Friday. iBio has a one year low of $0.68 and a one year high of $3.82. The company has a market capitalization of $57.78 million, a PE ratio of -2.93 and a beta of 1.47. The company's fifty day moving average price is $0.93 and its 200-day moving average price is $1.59.
iBio (NASDAQ:IBIO - Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. The business had revenue of $1.07 million during the quarter, compared to analysts' expectations of $0.03 million. On average, research analysts predict that iBio will post -0.36 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the business. Readystate Asset Management LP purchased a new position in shares of iBio during the third quarter worth about $26,000. Landscape Capital Management L.L.C. purchased a new stake in shares of iBio in the 3rd quarter valued at about $105,000. R Squared Ltd acquired a new stake in shares of iBio in the 3rd quarter valued at about $29,000. Squarepoint Ops LLC acquired a new stake in shares of iBio in the 2nd quarter valued at about $873,000. Finally, Headlands Technologies LLC boosted its position in shares of iBio by 333.0% in the 2nd quarter. Headlands Technologies LLC now owns 47,413 shares of the company's stock valued at $83,000 after purchasing an additional 36,463 shares during the period. Hedge funds and other institutional investors own 7.90% of the company's stock.
About iBio
(
Get Free Report)
iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company's current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iBio wasn't on the list.
While iBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.